Long-term dupilumab therapy in Netherton syndrome with severe atopic manifestations: Case report and review of the literature

Australas J Dermatol. 2023 May;64(2):272-277. doi: 10.1111/ajd.13986. Epub 2023 Feb 6.


We herein present a unique patient of Netherton syndrome (NS) with ichthyosis linearis circumflexa (ILC) lesions associated with severe atopic manifestations since infancy, showing different responses of atopic and ILC lesions to a 2-year dupilumab therapy. The atopic eczematous lesions and pruritus healed remarkably, dramatically improving the patient's quality of life, whilst the scalp hair showed a clinical and light microscopic improvement. The additional recovery in axillary/pubic/extremity hair growth, sweating and nail growth in the presented case was not previously reported in NS patients treated with dupilumab. However, dupilumab had no therapeutic effect on ILC lesions which were not pruritic and showed a treatment-independent wax and waned course.

Keywords: Netherton syndrome; atopic dermatitis; hypohidrosis; hypotrichosis; ichthyosis; pruritus; therapy-systemic.

Publication types

  • Review
  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Dermatitis, Atopic* / complications
  • Dermatitis, Atopic* / drug therapy
  • Dermatitis, Atopic* / pathology
  • Humans
  • Netherton Syndrome* / complications
  • Netherton Syndrome* / drug therapy
  • Netherton Syndrome* / pathology
  • Quality of Life


  • dupilumab
  • Antibodies, Monoclonal, Humanized